Advertisement
Screener

Jade Biosciences, Inc. (JBIO) Debt Securities, Trading, Unrealized Gain

3.2 / 5 stars · 21/33 Roast Me

Jade Biosciences, Inc. Debt Securities, Trading, Unrealized Gain

Jade Biosciences, Inc. (JBIO) reported Debt Securities, Trading, Unrealized Gain of $307.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.

Financial Statements › Income Statement › Other Income

us-gaap:DebtSecuritiesTradingUnrealizedGain · last filed 2025-03-27

  • Jade Biosciences, Inc. debt securities, trading, unrealized gain for the quarter ending 2024-09-30 was $307.00K, a 996.43% increase year-over-year.
  • Jade Biosciences, Inc. debt securities, trading, unrealized gain for the quarter ending 2023-09-30 was $28.00K, a 100.00% increase year-over-year.
  • Jade Biosciences, Inc. debt securities, trading, unrealized gain for the quarter ending 2023-03-31 was $265.00K.
  • Jade Biosciences, Inc. debt securities, trading, unrealized gain for the quarter ending 2022-09-30 was $14.00K.
  • Jade Biosciences, Inc. debt securities, trading, unrealized gain for fiscal 2023 was $703.00K.
Period endDebt Securities, Trading, Unrealized Gain 3 monthDebt Securities, Trading, Unrealized Gain 12 month
2024-09-30$307.00K
10-Q · filed 2024-11-12
2023-12-31$703.00K
10-K · filed 2025-03-27
2023-09-30$28.00K
10-Q · filed 2024-11-12
2023-03-31$265.00K
10-Q · filed 2024-11-12
2022-09-30$14.00K
10-Q · filed 2023-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Apnimed, Inc. (APMD)United States$0.899B
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03